Literature DB >> 1890697

Developmental and regional expression of choline acetyltransferase mRNA in the rat central nervous system.

C F Ibáñez1, P Ernfors, H Persson.   

Abstract

The developmental and regional expression of choline acetyltransferase (ChAT) mRNA was examined in the rat brain and spinal cord by northern blot analysis and in situ hybridization. ChAT mRNA expression in the brain showed a biphasic increase during development, with a first peak at two weeks postnatally, a marked decrease by the third week, and a second increase between the third and fifth week after birth, indicating that emergence of the cholinergic phenotype occurs at different times in different brain regions. In the spinal cord, ChAT mRNA was detected at similar levels from embryonic stage 13 (E13) until birth, increasing thereafter until adulthood. In the adult rat central nervous system, high levels of ChAT mRNA were detected in the spinal cord and brain stem structures. Lower levels were seen in midbrain, septum, striatum, thalamus, and olfactory bulb. ChAT mRNA containing cells were identified by in situ hybridization in the olfactory tubercule, piriform cortex, striatum, several basal forebrain nuclei, and spinal cord. A nearly two-fold increase in adult spinal cord ChAT mRNA levels were seen one week after a bilateral crush lesion of the sciatic nerve, indicating that ChAT mRNA expression is regulated during motoneuron regeneration.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1890697     DOI: 10.1002/jnr.490290205

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  8 in total

1.  Expression profiling of precuneus layer III cathepsin D-immunopositive pyramidal neurons in mild cognitive impairment and Alzheimer's disease: Evidence for neuronal signaling vulnerability.

Authors:  Bin He; Sylvia E Perez; Sang H Lee; Stephen D Ginsberg; Michael Malek-Ahmadi; Elliott J Mufson
Journal:  J Comp Neurol       Date:  2020-05-05       Impact factor: 3.215

2.  Effects of AF64A on gene expression of choline acetyltransferase (ChAT) in the septo-hippocampal pathway and striatum in vivo.

Authors:  Q I Fan; I Hanin
Journal:  Neurochem Res       Date:  1999-01       Impact factor: 3.996

3.  Galpha(olf) levels are regulated by receptor usage and control dopamine and adenosine action in the striatum.

Authors:  D Hervé; C Le Moine; J C Corvol; L Belluscio; C Ledent; A A Fienberg; M Jaber; J M Studler; J A Girault
Journal:  J Neurosci       Date:  2001-06-15       Impact factor: 6.167

4.  Distribution of the vesicular acetylcholine transporter (VAChT) in the central and peripheral nervous systems of the rat.

Authors:  M K Schäfer; E Weihe; H Varoqui; L E Eiden; J D Erickson
Journal:  J Mol Neurosci       Date:  1994       Impact factor: 3.444

5.  Brain region-specific alterations in the gene expression of cytokines, immune cell markers and cholinergic system components during peripheral endotoxin-induced inflammation.

Authors:  Harold A Silverman; Meghan Dancho; Angelique Regnier-Golanov; Mansoor Nasim; Mahendar Ochani; Peder S Olofsson; Mohamed Ahmed; Edmund J Miller; Sangeeta S Chavan; Eugene Golanov; Christine N Metz; Kevin J Tracey; Valentin A Pavlov
Journal:  Mol Med       Date:  2015-03-11       Impact factor: 6.354

6.  Lineage specification of neuronal precursors in the mouse spinal cord.

Authors:  L J Richards; M Murphy; R Dutton; T J Kilpatrick; A C Puche; B Key; S S Tan; P S Talman; P F Bartlett
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

7.  Regulatory region in choline acetyltransferase gene directs developmental and tissue-specific expression in transgenic mice.

Authors:  P Lönnerberg; U Lendahl; H Funakoshi; L Arhlund-Richter; H Persson; C F Ibáñez
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

8.  Frizzled3 controls axonal development in distinct populations of cranial and spinal motor neurons.

Authors:  Zhong L Hua; Philip M Smallwood; Jeremy Nathans
Journal:  Elife       Date:  2013-12-17       Impact factor: 8.140

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.